Skip to content

The effect of hemoglobin clearance rate on the prognosis of aneurysmal subarachnoid hemorrhage and angiographic negative subarachnoid hemorrhage patients

The effect of hemoglobin clearance rate on the prognosis of aneurysmal subarachnoid hemorrhage and angiographic negative subarachnoid hemorrhage patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042986
Enrollment
Unknown
Registered
2021-02-03
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid hemorrhage

Interventions

Aneurysmal subarachnoid hemorrhage group:lumbar puncture
Angiography negative subarachnoid hemorrhage group:lumbar puncture
control group:lumbar puncture

Sponsors

Department of Neurosurgery, Gulou Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The subjects or their entrusted family members voluntarily signed the informed consent of the trial; 2. Subjects aged 20-70 years old; 3. Subjects with negative angiography should be admitted within 72 hours of hemorrhage; Patients with aneurysmal subarachnoid hemorrhage should be treated by interventional surgery within 72 hours after aneurysm rupture; 4. Subjects with SAH, hunt Hess grade 1-4; 5. Control group: 20-70 years old subjects, no cerebrovascular disease and nervous system disease need lumbar epidural anesthesia of cesarean section subjects or volunteers.

Exclusion criteria

Exclusion criteria: 1. The subjects who did not meet the inclusion criteria, or the responsible physician decided that they were not suitable to participate in the trial; 2. Patients with severe cardiac insufficiency, renal insufficiency, diabetes or other serious diseases; 3. Patients with severe brain edema, massive intracranial hematoma or hydrocephalus; 4. Subjects who cannot be selected for any reason according to the researcher.

Design outcomes

Primary

MeasureTime frame
Haptoglobin;HO-1;CD163;

Countries

China

Contacts

Public ContactZong Zhuang

Gulou Hospital Affiliated to Medical College of Nanjing University

zhuangzong@126.com+86 15850560410

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026